Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women. / Otten, Julia; Ryberg, Mats; Mellberg, Caroline; Andersson, Tomas; Chorell, Elin; Lindahl, Bernt; Larsson, Christel; Holst, Jens Juul; Olsson, Tommy.

In: European Journal of Endocrinology, Vol. 180, No. 6, 2019, p. 417-427.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Otten, J, Ryberg, M, Mellberg, C, Andersson, T, Chorell, E, Lindahl, B, Larsson, C, Holst, JJ & Olsson, T 2019, 'Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women', European Journal of Endocrinology, vol. 180, no. 6, pp. 417-427. https://doi.org/10.1530/EJE-19-0082

APA

Otten, J., Ryberg, M., Mellberg, C., Andersson, T., Chorell, E., Lindahl, B., ... Olsson, T. (2019). Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women. European Journal of Endocrinology, 180(6), 417-427. https://doi.org/10.1530/EJE-19-0082

Vancouver

Otten J, Ryberg M, Mellberg C, Andersson T, Chorell E, Lindahl B et al. Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women. European Journal of Endocrinology. 2019;180(6):417-427. https://doi.org/10.1530/EJE-19-0082

Author

Otten, Julia ; Ryberg, Mats ; Mellberg, Caroline ; Andersson, Tomas ; Chorell, Elin ; Lindahl, Bernt ; Larsson, Christel ; Holst, Jens Juul ; Olsson, Tommy. / Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women. In: European Journal of Endocrinology. 2019 ; Vol. 180, No. 6. pp. 417-427.

Bibtex

@article{6045d055c736438f842db25a44fbf455,
title = "Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women",
abstract = "Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and glucagon measured during an OGTT are described. Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11{\%} at 6 months and 10{\%} at 24 months. In the control diet group, mean weight loss was 6{\%} after 6 and 24 months (P = 0.0001 and P = 0.049 for the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area under the curve (iAUC) for GLP-1 increased by 34 and 45{\%} after 6 and 24 months in the Paleolithic diet group and increased by 59{\%} after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The fasting glucagon increase correlated with the beta-hydroxybutyrate increase. Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon suppression may be caused by a catabolic state",
author = "Julia Otten and Mats Ryberg and Caroline Mellberg and Tomas Andersson and Elin Chorell and Bernt Lindahl and Christel Larsson and Holst, {Jens Juul} and Tommy Olsson",
year = "2019",
doi = "10.1530/EJE-19-0082",
language = "English",
volume = "180",
pages = "417--427",
journal = "European Journal of Endocrinology. Supplement",
issn = "0804-4635",
publisher = "BioScientifica Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women

AU - Otten, Julia

AU - Ryberg, Mats

AU - Mellberg, Caroline

AU - Andersson, Tomas

AU - Chorell, Elin

AU - Lindahl, Bernt

AU - Larsson, Christel

AU - Holst, Jens Juul

AU - Olsson, Tommy

PY - 2019

Y1 - 2019

N2 - Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and glucagon measured during an OGTT are described. Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11% at 6 months and 10% at 24 months. In the control diet group, mean weight loss was 6% after 6 and 24 months (P = 0.0001 and P = 0.049 for the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area under the curve (iAUC) for GLP-1 increased by 34 and 45% after 6 and 24 months in the Paleolithic diet group and increased by 59% after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The fasting glucagon increase correlated with the beta-hydroxybutyrate increase. Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon suppression may be caused by a catabolic state

AB - Objective: To investigate how weight loss by different diets impacts postprandial levels of glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Methods: In this single-centre, parallel group 2-year trial, 70 healthy postmenopausal obese women were randomised to the Paleolithic diet or a healthy control diet based on Nordic Nutrition Recommendations. Both diets were without calorie restriction. The primary outcome was the change in fat mass. Here, secondary analyses on GLP-1, GIP and glucagon measured during an OGTT are described. Results: In the Paleolithic diet group, mean weight loss compared to baseline was 11% at 6 months and 10% at 24 months. In the control diet group, mean weight loss was 6% after 6 and 24 months (P = 0.0001 and P = 0.049 for the comparison between groups at 6 and 24 months respectively). Compared to baseline, the mean incremental area under the curve (iAUC) for GLP-1 increased by 34 and 45% after 6 and 24 months in the Paleolithic diet group and increased by 59% after 24 months in the control diet group. The mean iAUC for GIP increased only in the Paleolithic diet group. The area under the curve (AUC) for glucagon increased during the first 6 months in both groups. The fasting glucagon increase correlated with the beta-hydroxybutyrate increase. Conclusions: Weight loss caused an increase in postprandial GLP-1 levels and a further rise occurred during weight maintenance. Postprandial GIP levels increased only after the Paleolithic diet. Reduced postprandial glucagon suppression may be caused by a catabolic state

U2 - 10.1530/EJE-19-0082

DO - 10.1530/EJE-19-0082

M3 - Journal article

VL - 180

SP - 417

EP - 427

JO - European Journal of Endocrinology. Supplement

JF - European Journal of Endocrinology. Supplement

SN - 0804-4635

IS - 6

ER -

ID: 227696442